Related Experiment Videos
Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation
P Kearney1, M Suter, J C Biggs
1Haematology Department, St Vincent's Hospital Darlinghurst, Darlinghurst, NSW 2010, Sydney, Australia. phil.kearney@activebiotech.com
Leukemia Research
|December 6, 2001
Summary
This study details a chronic myeloid leukaemia (CML) patient who relapsed 12 years after a bone marrow transplant. The relapse involved a complex evolving karyotype, highlighting long-term monitoring needs for CML survivors.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Allogeneic bone marrow transplantation (BMT) offers a potential cure for chronic myeloid leukaemia (CML).
- Successful outcomes are well-documented for CML patients transplanted in the chronic phase.
- However, achieving similar success in advanced CML phases remains challenging.
Observation:
- This report describes a CML patient who underwent allogeneic BMT during the accelerated phase of the disease.
- Post-transplant monitoring confirmed donor chimerism and molecular remission (BCR-ABL mRNA absence).
Findings:
- The patient experienced a relapse nearly 12 years post-transplant.
- Cytogenetic analysis revealed a complex and evolving karyotype at relapse.
- Longitudinal molecular analyses using real-time and VNTR PCR correlated with these cytogenetic findings.
Implications:
- This case underscores the possibility of late relapses in CML patients post-BMT, even after achieving molecular remission.
- The complex karyotype evolution suggests underlying genomic instability contributing to relapse.
- Long-term, vigilant cytogenetic and molecular monitoring is crucial for detecting and managing late relapses in CML survivors.